 | Up a level |
2022
Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., Mueller, F., Desuki, A., Lueke, F., Wiegert, E., Flemmig, C., Schulz-Eying, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2022). BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. Ann. Oncol., 33 (7). S. S1404 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Wiegert, E., Schulz, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2021). BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors. Ann. Oncol., 32. S. S1392 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2020
Borchmann, P., Juehling, A., Goedel, P., Balke-Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Preussner, L., Zadoyan, G., Hanssens, L., Kaiser, A., Jurk, M., Buerger, I, Schneider, D., Dropulic, B., Overstijns, T., Holtick, U., Scheid, C., Miltenyi, S. and Hallek, M. (2020). Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 56 - 57. BASEL: KARGER. ISSN 2296-5262